Abstract
Nine patients with multifocal motor neuropathy who had previously responded favorably to IV immunoglobulins (IVIg) were treated with interferon-beta1a. Muscle strength and disability were evaluated. In six patients there was no effect of treatment. Four patients deteriorated in such a way that IVIg had to be restarted during the study. Three patients showed an improvement that was more pronounced than on IVIg. These patients had a shorter disease duration and were less affected clinically and electrophysiologically than those who did not respond.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Action Potentials / drug effects
-
Adult
-
Age of Onset
-
Demyelinating Autoimmune Diseases, CNS / drug therapy*
-
Female
-
Humans
-
Immunoglobulins, Intravenous / therapeutic use
-
Injections, Subcutaneous
-
Interferon beta-1a
-
Interferon-beta / therapeutic use*
-
Male
-
Middle Aged
-
Motor Neuron Disease / drug therapy*
-
Motor Neurons / drug effects
-
Motor Neurons / physiology
-
Muscle Contraction / drug effects
-
Neural Conduction / drug effects
-
Neurophysins
-
Peripheral Nerves / drug effects
-
Peripheral Nerves / physiopathology
-
Psychomotor Performance / drug effects
-
Treatment Outcome
Substances
-
Immunoglobulins, Intravenous
-
Neurophysins
-
Interferon-beta
-
Interferon beta-1a